BioScrip (BIOS) Receives Daily Media Impact Score of 0.15

News stories about BioScrip (NASDAQ:BIOS) have been trending somewhat positive on Saturday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. BioScrip earned a news sentiment score of 0.15 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.8943458799183 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Here are some of the news articles that may have impacted Accern Sentiment Analysis’s analysis:

Shares of BioScrip (NASDAQ BIOS) opened at $2.61 on Friday. The company has a debt-to-equity ratio of -6.11, a current ratio of 1.91 and a quick ratio of 1.60. BioScrip has a 52-week low of $0.98 and a 52-week high of $3.39.

BioScrip (NASDAQ:BIOS) last issued its quarterly earnings results on Thursday, November 2nd. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.02). The business had revenue of $198.70 million for the quarter, compared to analysts’ expectations of $202.91 million. During the same quarter in the previous year, the business earned ($0.12) earnings per share. BioScrip’s quarterly revenue was down 11.5% on a year-over-year basis. sell-side analysts expect that BioScrip will post -0.63 earnings per share for the current year.

Several research firms recently commented on BIOS. ValuEngine cut shares of BioScrip from a “hold” rating to a “sell” rating in a research report on Tuesday, August 22nd. Zacks Investment Research cut shares of BioScrip from a “buy” rating to a “hold” rating in a research report on Monday, August 14th. BidaskClub cut shares of BioScrip from a “buy” rating to a “hold” rating in a research report on Thursday, August 17th. Finally, SunTrust Banks reaffirmed a “buy” rating and issued a $3.00 price objective on shares of BioScrip in a research report on Friday, November 3rd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. BioScrip presently has a consensus rating of “Hold” and a consensus target price of $3.60.

In other news, CEO Daniel E. Greenleaf acquired 15,000 shares of the stock in a transaction dated Thursday, November 9th. The shares were bought at an average cost of $2.03 per share, for a total transaction of $30,450.00. Following the purchase, the chief executive officer now directly owns 31,000 shares of the company’s stock, valued at $62,930. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Michael G. Bronfein sold 27,000 shares of the business’s stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $2.69, for a total transaction of $72,630.00. Following the transaction, the director now owns 129,669 shares in the company, valued at $348,809.61. The disclosure for this sale can be found here. Insiders own 0.80% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at

About BioScrip

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Insider Buying and Selling by Quarter for BioScrip (NASDAQ:BIOS)

Receive News & Ratings for BioScrip Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc and related companies with's FREE daily email newsletter.

Leave a Reply